ACAD Acadia Pharmaceuticals Inc
- Pharmaceutical Preparation Manufacturing
15 minute delayed price. Price provided by IEX Cloud. The content contained therein is being provided to you for informational purposes only, does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and does not constitute a recommendation by GoScour to buy, sell, or hold any security, financial product, or instrument referenced in the content. GoScour is not liable for any errors or delays in content, or for any actions taken in reliance on any content.
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.